Sympathetic cardiac denervation might be driven by alpha-synuclein pathology, suggesting that in vivo testing for sympathetic cardiac denervation could allow clinical differentiation between Alzheimer’s disease (AD) and Alzheimer’s disease with comorbid dementia and Lewy bodies (AD/DLB).
Why this matters ?
Comorbid Lewy body pathology is very common in AD, yet there is currently no in vivo test to identify this. Developing a test that can differentiate living patients with AD from patients with AD/DLB would aid physicians in providing more effective treatment.
Want to read more?
Log in or sign up to access all Neurodiem content.
Already have an account? Log In
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.